Why the study?
Does long-term N-acetylprocainamide therapy reduce the frequency of premature ventricular complexes in patients with chronic ventricular arrhythmias?
Does long-term N-acetylprocainamide therapy reduce the frequency of premature ventricular complexes in patients with chronic ventricular arrhythmias?
Long-term N-acetylprocainamide therapy maintains its antiarrhythmic effect without tolerance development in patients with chronic ventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
May support sustained PVC suppression with long-term NAPA without tolerance; hypothesis-generating and requires randomized confirmation before clinical use.
Four patients with chronic ventricular arrhythmias, shown to respond over the short term to N-acetylprocainamide (NAPA), were treated for between 3 and 4 yr with NAPA, and 24-hr ambulatory ECGs were obtained monthly to monitor their responses. When the patients were ambulatory and receiving NAPA, the mean frequency of premature ventricular complexes averaged 70% (range 60% to 82%) below that recorded at 6-mo intervals when the patients were hospitalized and receiving placebo. Analysis of variance showed that NAPA exerted an antiarrhythmic effect in these patients and that tolerance to this effect did not develop with long-term therapy. Plasma NAPA concentrations required to achieve this level of response averaged 21 micrograms/ml (12 to 35 micrograms/ml) and were roughly twice as high as those which appeared to be maximally effective when the patients were hospitalized for their initial evaluation. NAPA therapy was associated with positive antibody titers in only one patient and seems less prone to cause drug-induced lupus erythematosus than procainamide, but NAPA shares the gastrointestinal and other side effects of procainamide.
No takes yet. Share an insight, caveat, or question.
Atkinson et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: